Notwithstanding encouraging clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from managed care entities. These organizations are often erecting obstacles to access, such as high expense criteria and PA that restrict patient availability. Analysts in… Read More